Needham & Company reiterates a 'Buy' on Gilead Sciences (NASDAQ: GILD), PT $48.

Needham analyst says, "Concerns around long-term ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE